NCT06186414 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2030

Conditions

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Interventions

DRUG

SIM0237

Several dose levels of SIM0237 will be administered as a single agent for evaluation

DRUG

SIM0237 and BCG

Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

DRUG

SIM0237

RD level of SIM0237 will be administered as a single agent for evaluation

DRUG

SIM0237 and BCG

RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Trial Locations (14)

30012

NOT_YET_RECRUITING

First Hospital of Shanxi Medcial University, Taiyuan

100191

RECRUITING

Peking University Third Hospital, Beijing

150000

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Haerbin

200092

NOT_YET_RECRUITING

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

201321

ENROLLING_BY_INVITATION

Fudan University Shanghai Cancer Center, Shanghai

250012

NOT_YET_RECRUITING

Qilu Hospital of Shandong University, Jinan

266071

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

300211

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

325015

NOT_YET_RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

410031

RECRUITING

Hunan Cancer Hospital, Changsha

430060

NOT_YET_RECRUITING

Renmin Hospital of Wuhan University, Wuhan

450003

NOT_YET_RECRUITING

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

610041

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu